Rapport Therapeutics(NASDAQ) RAPP

Rapport Therapeutics, Inc. makes medicines for people with brain disorders. These treatments help control seizures and manage mood swings. The company aims to reduce side effects found in traditional drugs.

What is in the Pipeline?

• RAP-219: Experimental small molecule designed to treat drug-resistant focal epilepsy and bipolar mania; acts as a negative allosteric modulator to reduce brain activity associated with seizures.
• Bipolar Mania Treatment: Clinical-stage program using RAP-219 to address mood disorders; currently in Phase 2 testing with results expected in late 2026.
• Chronic Pain Research: Discovery-stage programs targeting specific receptors in sensory neurons; focuses on providing non-opiate options for long-term pain and migraines.
• Hearing Impairment Therapy: Early-stage research into molecules that could treat hearing and balance disorders; targets specific nicotinic receptors in the ear.

Growth and Strategy

• Entered a worldwide license agreement with Janssen Pharmaceutical NV in August 2022 to research and commercialize products targeting specific brain receptors.
• Partnered with NeuroPace Inc. in November 2023 to collect and analyze brain data from patients during epilepsy clinical trials.
• Formed a collaboration with Tenacia Biotechnology in March 2026 to develop and commercialize RAP-219 in mainland China, Hong Kong, Macau, and Taiwan.
• Initiated a global Phase 3 clinical program for the lead drug candidate RAP-219 in the second quarter of 2026.

Precise Brain Targeting

Rapport uses a proprietary technology platform to identify receptor-associated proteins that control how signals move through specific regions of the brain. This precision approach allows the company to target diseased tissues while avoiding the hindbrain, which helps reduce the common side effects of neurology drugs.

Tracking the Financial Results

• Collaboration revenue was $20.0 million for the six-month period ended June 30, 2026, following an upfront payment from Tenacia.
• Net loss was $76.5 million for the six-month period ended June 30, 2026, compared to $50.8 million for the same period in 2025.
• Research and development expenses were $84.1 million for the six-month period ended June 30, 2026.
• Market capitalization was $2.0 billion in Q2 2026, up 390.9% year over year.
• Total cash, cash equivalents, and short-term investments were $436.1 million as of June 30, 2026.

Bottom Line

Rapport has transitioned from an early discovery startup to a clinical-stage firm with a global partnership and multiple late-stage trials. Its focus on precision targeting and expansion into diverse neurological indications support its long-term development strategy.